Insilico Medicine (“Insilico”; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the nomination of ISM9077, the AI-empowered, potential first-in-class Target Y inhibitor with pipeline-in-a-drug potential, as a Preclinical Candidate (PCC) for the treatment of ocular diseases including dry Age-Related Macular Degeneration (dry AMD), uveitis, and dry eye disease. As the 32nd PCC nominated since 2021, ISM9077 boasts potent inhibition across species, excellent exposure and permeability traits, and a favorable safety profile in preclinical studies.

A new review article highlights a rapidly emerging frontier in oncology: the dynamic and influential relationship between nerves and tumors. This evolving field is reshaping how scientists and clinicians understand cancer progression, revealing that tumors are not isolated masses but part of a complex, interactive tumor microenvironment that includes neural networks alongside immune and stromal components.

A new review highlights the growing importance of circular RNAs (circRNAs) in addressing one of the most pressing challenges in modern oncology: treatment-related toxicity. As advances in cancer therapies continue to improve survival rates worldwide, adverse effects linked to chemotherapy, radiotherapy, and immunotherapy remain a critical barrier to long-term patient outcomes and quality of life.

A comprehensive new review article highlights the growing importance of the MYH9 gene as a central player in both cancer biology and inherited genetic conditions, offering fresh perspectives on its potential as a therapeutic target.

A new review highlights how advances in DNA technology are reshaping the future of healthcare by shifting the focus from treatment to prevention. Cutting-edge tools are enabling earlier detection of risk and more precise intervention at the genetic level, offering the potential to stop diseases before symptoms ever appear.

A growing body of evidence is reshaping how cancer is understood, placing the spotlight on intra-tumoral microbiota as powerful yet previously overlooked players within the tumor microenvironment. Far from being sterile, tumors host complex communities of bacteria, fungi, and viruses that actively influence disease progression, immune responses, and treatment outcomes.